Skip to main content
Skip to navigation

Featured Profile: John Lauriello


John Lauriello

Nationally recognized schizophrenia researcher Dr. John Lauriello works to advance diagnosis and treatment for patients and practitioners.

Lauriello has studied and written extensively on the diagnostic features, biomarkers and pharmacological interventions for schizophrenia, a severe and disabling disorder that often strikes individuals just as they enter adulthood. Working with brain imaging colleagues, Lauriello has helped investigate potential markers of early psychotic disorders using Magnetic Resonance Imaging (MRI). He has also been part of several large pharmaceutical trials for the National Institute of Mental Health and within the medical industry which have led to treatments currently in use.

Lauriello is an international expert in the area of long-acting injectable (LAI) antipsychotics, which may be more effective than oral dosing for many patients. The Oxford Press Antipsychotic Long Acting Injections, which he co-authored and edited, is the most comprehensive work on this subject. Lauriello also co-authored/edited American Psychiatric Publishing’s Clinical Manual for Treatment of Schizophrenia, which provides a patient-centered perspective on illness management.

In 2014, Lauriello was elected to membership in the American College of Psychiatrists. The election signifies his national recognition as an expert in psychiatry.

Dr. John Lauriello is Professor and Chairman of Psychiatry and the Robert J. Douglas and Betty Douglas Distinguished Faculty Scholar in Psychiatry in the University of Missouri School of Medicine and Executive Medical Director of the Missouri Psychiatric Center.

Click here to download a PDF of this story.

Related Initiative(s):
One Health/One Medicine